Eli Lilly signs 2.75 billion dollar AI drug development deal
Insilico Medicine and Eli Lilly agreed to a 2.75 billion dollar drug deal today. Lilly will develop preclinical candidates and pay 115 million dollars upfront.
Xurve View
Insights:
Xurve View
Generative-AI drug developer Insilico Medicine announced on Sunday a major global licensing and research agreement with the United States pharmaceutical leader Eli Lilly and Company. The partnership, which focuses on the development of preclinical oral drug candidates, is valued at up to $2.75 billion, contingent on the achievement of specific milestones.
